Inactive Instrument

News LENZ Therapeutics, Inc. OTC Markets

Equities

LENZ Therapeutics : Key Opinion Leader Presentation of Capstone Data from Phase 3 CLARITY Study	Jun. 17	PU
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024	Jun. 10	GL
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference	May. 30	GL
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates	May. 08	GL
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024	May. 01	GL
Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target	Apr. 15	MT
William Blair Starts LENZ Therapeutics With Outperform Rating	Apr. 15	MT
LENZ Therapeutics Reports Positive Topline Data From Late-Stage Presbyopia Trials	Apr. 03	MT
LENZ Therapeutics, Inc. Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials	Apr. 03	CI
Lenz Therapeutics' eye disease drugs meet main goal of late-stage study	Apr. 03	RE
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials	Apr. 03	BU
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials	Apr. 02	BU
Piper Sandler Initiates LENZ Therapeutics at Overweight With $28 Price Target	Mar. 27	MT
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) added to NASDAQ Composite Index	Mar. 24	CI

No results for this search